1-anilino-8-naphthalenesulfonate has been researched along with Hyperlipoproteinemia Type III in 24 studies
1-anilino-8-naphthalenesulfonate: RN given refers to parent cpd
8-anilinonaphthalene-1-sulfonic acid : A naphthalenesulfonic acid that is naphthalene-1-sulfonic acid substituted by a phenylamino group at position 8.
Hyperlipoproteinemia Type III: An autosomal recessively inherited disorder characterized by the accumulation of intermediate-density lipoprotein (IDL or broad-beta-lipoprotein). IDL has a CHOLESTEROL to TRIGLYCERIDES ratio greater than that of VERY-LOW-DENSITY LIPOPROTEINS. This disorder is due to mutation of APOLIPOPROTEINS E, a receptor-binding component of VLDL and CHYLOMICRONS, resulting in their reduced clearance and high plasma levels of both cholesterol and triglycerides.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ten patients with type III and 10 with type IV hyperlipoproteinemia participated in a comparative open cross-over study of the effect of acipimox (750 mg/day) and clofibrate (2 g/day) on lipoproteins, apoliproproteins and postheparin lipase activities during 6 weeks." | 2.66 | A comparative study of the effects of acipimox and clofibrate in type III and type IV hyperlipoproteinemia. ( Demacker, PN; Stalenhoef, AF; Stuyt, PM; Van 't Laar, A, 1985) |
| "It was subsequently shown that the lipemia was adequately controlled by diet." | 1.24 | STUDIES OF THE INFLUENCE OF DIET ON CLEARING-FACTOR LIPASE (CFL) AND BLOOD LIPID LEVELS OF A PATIENT WITH HYPERLIPIDEMIA. ( MACMILLAN, RL; MACNAB, M; MONKHOUSE, FC, 1965) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (37.50) | 18.7374 |
| 1990's | 4 (16.67) | 18.2507 |
| 2000's | 3 (12.50) | 29.6817 |
| 2010's | 8 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lane-Donovan, C | 1 |
| Herz, J | 1 |
| Mak, AC | 1 |
| Pullinger, CR | 1 |
| Tang, LF | 1 |
| Wong, JS | 1 |
| Deo, RC | 1 |
| Schwarz, JM | 1 |
| Gugliucci, A | 1 |
| Movsesyan, I | 1 |
| Ishida, BY | 1 |
| Chu, C | 1 |
| Poon, A | 1 |
| Kim, P | 1 |
| Stock, EO | 1 |
| Schaefer, EJ | 1 |
| Asztalos, BF | 1 |
| Castellano, JM | 1 |
| Wyss-Coray, T | 1 |
| Duncan, JL | 1 |
| Miller, BL | 1 |
| Kane, JP | 2 |
| Kwok, PY | 1 |
| Malloy, MJ | 2 |
| Laskowitz, DT | 1 |
| Kernagis, DN | 1 |
| Cullum, CM | 1 |
| Weiner, MF | 1 |
| Malloy, M | 1 |
| Miller, B | 1 |
| Kane, J | 1 |
| Schaefer, JR | 1 |
| Henneman, P | 1 |
| van der Sman-de Beer, F | 1 |
| Moghaddam, PH | 1 |
| Huijts, P | 1 |
| Stalenhoef, AF | 2 |
| Kastelein, JJ | 1 |
| van Duijn, CM | 1 |
| Havekes, LM | 1 |
| Frants, RR | 1 |
| van Dijk, KW | 1 |
| Smelt, AH | 1 |
| Murase, T | 1 |
| Ebara, T | 1 |
| Okubo, M | 1 |
| MACNAB, M | 1 |
| MACMILLAN, RL | 1 |
| MONKHOUSE, FC | 1 |
| SANDHOFER, F | 1 |
| SAILER, S | 1 |
| HERBST, M | 1 |
| BRAUNSTEINER, H | 1 |
| Schonfeld, G | 1 |
| Ehnholm, C | 2 |
| Mahley, RW | 2 |
| Chappell, DA | 1 |
| Weisgraber, KH | 1 |
| Ludwig, E | 1 |
| Witztum, JL | 1 |
| Beisiegel, U | 1 |
| Krapp, A | 1 |
| Weber, W | 1 |
| Olivecrona, G | 1 |
| Ji, ZS | 1 |
| Tada, N | 1 |
| Hegele, RA | 1 |
| Tu, L | 1 |
| Connelly, PW | 1 |
| Feussner, G | 1 |
| von Hodenberg, E | 1 |
| Ziegler, R | 1 |
| Zannis, VI | 2 |
| Breslow, JL | 1 |
| Breier, C | 1 |
| Gustafson, S | 1 |
| Vessby, B | 1 |
| Ostlund-Lindqvist, AM | 1 |
| Stuyt, PM | 1 |
| Demacker, PN | 1 |
| Van 't Laar, A | 1 |
| Schmitz, G | 1 |
| Assmann, G | 1 |
| Augustin, J | 1 |
| Dirkes-Kersting, A | 1 |
| Brennhaüsen, B | 1 |
| Karoff, C | 1 |
| Georgiadou, D | 1 |
| Chroni, A | 1 |
| Vezeridis, A | 1 |
| Stratikos, E | 1 |
4 reviews available for 1-anilino-8-naphthalenesulfonate and Hyperlipoproteinemia Type III
| Article | Year |
|---|---|
Disorders of lipid transport: relationship to abnormalities of apoproteins, enzymes and cellular receptors.
Topics: Abetalipoproteinemia; Apolipoproteins; Apoproteins; Female; Humans; Hyperlipoproteinemia Type III; H | 1984 |
Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E.
Topics: Alzheimer Disease; Animals; Apolipoproteins E; Biological Transport, Active; Cell Membrane; Chylomic | 1999 |
[Remnant hyperlipidemia].
Topics: Apolipoproteins; Cholesterol; Diagnosis, Differential; Humans; Hyperlipidemia, Familial Combined; Hy | 2001 |
Genetic mutations affecting human lipoprotein metabolism.
Topics: Abetalipoproteinemia; Amino Acid Sequence; Animals; Apolipoprotein A-I; Apolipoproteins A; Apolipopr | 1985 |
1 trial available for 1-anilino-8-naphthalenesulfonate and Hyperlipoproteinemia Type III
| Article | Year |
|---|---|
A comparative study of the effects of acipimox and clofibrate in type III and type IV hyperlipoproteinemia.
Topics: Adult; Aged; Apolipoprotein A-I; Apolipoprotein A-II; Apolipoproteins A; Apolipoproteins B; Choleste | 1985 |
19 other studies available for 1-anilino-8-naphthalenesulfonate and Hyperlipoproteinemia Type III
| Article | Year |
|---|---|
Is apolipoprotein e required for cognitive function in humans?: implications for Alzheimer drug development.
Topics: Apolipoproteins E; Humans; Hyperlipoproteinemia Type III; Lipase; Male; Multidrug Resistance-Associa | 2014 |
Effects of the absence of apolipoprotein e on lipoproteins, neurocognitive function, and retinal function.
Topics: Adult; Apolipoproteins A; Apolipoproteins C; Apolipoproteins E; Carotid Artery Diseases; Exercise Te | 2014 |
Congenital absence of apolipoprotein E and neurological function.
Topics: Apolipoproteins E; Humans; Hyperlipoproteinemia Type III; Lipase; Male; Multidrug Resistance-Associa | 2014 |
Congenital absence of apolipoprotein E and neurological function-reply.
Topics: Apolipoproteins E; Humans; Hyperlipoproteinemia Type III; Lipase; Male; Multidrug Resistance-Associa | 2014 |
Apolipoprotein E and neurocognitive function.
Topics: Apolipoproteins E; Humans; Hyperlipoproteinemia Type III; Lipase; Male; Multidrug Resistance-Associa | 2015 |
Apolipoprotein E and neurocognitive function--in reply.
Topics: Apolipoproteins E; Humans; Hyperlipoproteinemia Type III; Lipase; Male; Multidrug Resistance-Associa | 2015 |
Unraveling hyperlipidemia type III (dysbetalipoproteinemia), slowly.
Topics: Alleles; Apolipoprotein A-V; Apolipoprotein C-III; Apolipoproteins A; Gene Frequency; Genotype; Huma | 2009 |
The expression of type III hyperlipoproteinemia: involvement of lipolysis genes.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Apolipoprotein A-V; Apolipoprotein C-III; Apolipoproteins A | 2009 |
Hepatic lipase activity is decreased in Japanese patients with type III hyperlipoproteinemia.
Topics: Adult; Enzyme Activation; Female; Humans; Hyperlipoproteinemia Type III; Lipase; Male; Middle Aged | 2012 |
STUDIES OF THE INFLUENCE OF DIET ON CLEARING-FACTOR LIPASE (CFL) AND BLOOD LIPID LEVELS OF A PATIENT WITH HYPERLIPIDEMIA.
Topics: Blood Chemical Analysis; Chylomicrons; Diet; Diet Therapy; Heparin; Humans; Hyperlipidemias; Hyperli | 1965 |
[STUDIES ON THE POST HEPARINIC LIPOPRPTEIN LIPASE ACTIVITY IN 6 CASES OF ESSENTIAL HYPERLIPEMIA].
Topics: Clinical Enzyme Tests; Heparin; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type I; | 1965 |
Role of apolipoprotein E in the lipolytic conversion of beta-very low density lipoproteins to low density lipoproteins in type III hyperlipoproteinemia.
Topics: Animals; Apolipoproteins; Apolipoproteins E; Cattle; Dogs; Female; Heparin; Humans; Hyperlipoprotein | 1984 |
The role of alpha 2M receptor/LRP in chylomicron remnant metabolism.
Topics: alpha-Macroglobulins; Amino Acid Sequence; Animals; Apolipoprotein C-II; Apolipoproteins C; Apolipop | 1994 |
Human hepatic lipase mutations and polymorphisms.
Topics: Alleles; Amino Acid Sequence; Base Sequence; DNA; DNA Mutational Analysis; Gene Frequency; Genetic V | 1992 |
Atypical type III hyperlipoproteinemia in a patient with Ig A myelomatosis.
Topics: Cholesterol, VLDL; Female; Humans; Hyperlipoproteinemia Type III; Immunoglobulin A; Lipase; Lipoprot | 1990 |
[Pathologic decrease in lipoprotein lipase activity in relation to the development of hyperlipemias and their significance for coronary heart disease].
Topics: Adult; Alcoholism; Cholesterol; Coronary Disease; Humans; Hydrogen-Ion Concentration; Hyperlipoprote | 1986 |
HDL from type III dysbetalipoproteinaemic patients show decreased capacity to inhibit VLDL uptake in rat liver endothelial cells.
Topics: Adult; Animals; Apolipoproteins E; Dietary Fats; Endothelium; Humans; Hyperlipoproteinemia Type III; | 1986 |
Characterization of very low density lipoproteins and intermediate density lipoproteins of normo- and hyperlipidemic apolipoprotein E-2 homozygotes.
Topics: Adult; Animals; Apolipoprotein E2; Apolipoproteins E; Cholesterol; Cholesterol Esters; Electrophores | 1985 |
Biophysical analysis of apolipoprotein E3 variants linked with development of type III hyperlipoproteinemia.
Topics: Anilino Naphthalenesulfonates; Apolipoprotein E3; Astrocytoma; Biophysics; Circular Dichroism; Fluor | 2011 |